Gilead Sciences Inc. could be granted additional emergency use authorization by US regulators for its drug remdesivir to include patients hospitalized with moderate COVID-19, despite recent mixed trial results, the company’s top research executive told Reuters on Friday.Data published by Gilead (GILD) on Friday showed that a 5-day course of intravenous remdesivir modestly helped less severely ill COVID-19 patients, but a 10-day course did not show a benefit.Back in May, the US Food and Drug Administration (FDA) approved sales of remdesivir on an emergency basis for patients hospitalized with severe COVID-19, the disease caused by the new coronavirus, after trial …read more
Source:: Yahoo Finance
